C:\laam\lamAPA.ppt 8/04/98 Heroin Addiction Treatment: A Comparison of Methadone and LAAM M. Douglas Anglin, Ph.D. Douglas Longshore, Ph.D. Jeffrey J.

Slides:



Advertisements
Similar presentations
XR-NTX Implementation in Los Angeles County Desirée A. Crèvecoeur-MacPhail, PhD UCLA Integrated Substance Abuse Programs Santa Monica Blvd., Suite.
Advertisements

1 Arlene Ash QMC - Third Tuesday September 21, 2010 (as amended, Sept 23) Analyzing Observational Data: Focus on Propensity Scores.
Drug Use and HIV Risk Behaviors among HIV-positive Latino MSM in a Large Urban Setting Jesus Felizzola, MD Mario De La Rosa, PhD Florida International.
Background: The low retention rates among African Americans in substance abuse treatment (Milligan et al., 2004) combined with the limited number of treatments.
Differences in Characteristics of Heroin Inhalers and Injectors at Admission to Treatment J. C. Maxwell, R. T. Spence, & T. M. Bohman UT Center for Social.
Delay from Testing HIV Positive until First HIV Care for Drug Users: Adverse Consequences and Possible Solutions Barbara J Turner MD, MSEd* John Fleishman.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence July–August 2013.
Syphilis and HIV screening initiatives in North Carolina jails Lynne A. Sampson PhD, MPH HIV/STD Update September 25, 2008.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence September–October 2008.
HIV INTERVENTION FOR PROVIDERS (HIP) Principal Investigators:  Carol Dawson Rose, RN, Ph.D. and Grant Colfax, MD. Co-Investigators:  Cynthia Gomez, Ph.D.,
Journal Club Alcohol, Other Drugs, and Health: Current Evidence September–October 2009.
Predictors of HIV Transmission Risk among Patients in Care: Results from the SPNS Prevention with Positives Initiative Stephen F. Morin, PhD Principal.
Motivational Interviewing to Improve Treatment Engagement and Outcome* The effect of one session on retention Research findings from the NIDA Clinical.
Copyright Alcohol Medical Scholars Program 1 Opioid Agonist Treatment: “Trading one substance for another?” Joseph Sakai, M.D.
Slide 1 of 20 Overview of National Treatment Outcome Studies Charts Prepared & Released for Public Use by Dwayne Simpson (TCU), Robert Hubbard (NDRI-NC),
Psychopharmacotherapy in Correctional Institutions Robert P. Schwartz, M.D. Friends Research Institute Supported by NIDA R01 DA (PI: Kinlock)
UCLA Drug Abuse Research CenterForever Free Evaluation Forever Free Substance Abuse Treatment Program Outcomes Study Michael Prendergast, Ph.D., Principal.
HIV Risk Reduction With Buprenorphine- Naloxone or Methadone: Findings From A Randomized Trial G. Woody, D. Bruce, P. T. Korthuis, S. Chhatre, M. Hillhouse,
Practical Application of Contingency Management Michael J. McCann, MA Matrix Institute on Addictions.
Suboxone as an Adjunctive Medication, Not Maintenance Dennis M. Donovan, Ph.D. UW Alcohol & Drug Abuse Institute Patricia C. Knox, Ph.D. Recovery Centers.
Medication Assisted Therapy for Opioid Addiction: Methadone and Buprenorphine Andrew J. Saxon, M.D. Veterans Affairs Puget Sound Health Care System and.
Richard Rawson, Ph.D. Valerie Pearce, M.P.H. Rachel Gonzales, Ph.D. Julie Brummer, B.A. UCLA Integrated Substance Abuse Programs May 8, 2007 Treatment.
Results of the Vivitrol Pilot in Los Angeles County Presented by: Desiree A. Crevecoeur-MacPhail, Ph.D. Research Psychologist, UCLA ISAP.
UCLA’s Statewide Evaluation of Proposition 36 Darren Urada, Ph.D. UCLA Integrated Substance Abuse Programs Association for Criminal Justice Research (California)
Impact of Online Counseling Farrokh Alemi, Ph.D..
Outcomes of Treatment for Methamphetamine Use: LA County (“Treatment-as-Usual”) M.-L. Brecht UCLA Integrated Substance Abuse Programs CATES 3/30/2004.
The University of Georgia The Treatment of Oxycodone Abuse: Organizational Predictors of Admissions Hannah K. Knudsen Lori J. Ducharme J. Aaron Johnson.
CARIBBEAN BASIN AND HISPANIC ADDICTION TECHNOLOGY TRANSFER CENTER Effects of a Two-facet Intervention to Reduce HIV Risk Behaviors Among Hispanic Drug.
INTRODUCTION Many studies conducted in 1950’s and 1960’s suggest that hallucinogen assisted psychedelic psychotherapy may offer an effective treatment.
Managing Hard-to-Manage Patients Sharon Stancliff, MD Medical Consultant New York State Department of Health AIDS Institute New York, NY.
Raymond F. Anton, MD for The COMBINE Study Research Group
Participants were recruited from 6 drug free, psychosocial treatment (PT) and 5 methadone maintenance (MM) programs (N = 628) participating in a NIDA Clinical.
Abstinence Incentives for Methadone Maintained Stimulant Users: Outcomes for Those Testing Stimulant Positive vs Negative at Study Intake Maxine L. Stitzer.
EFFICACY OF A STAGE-BASED BEHAVIORAL INTERVENTION TO PROMOTE STI SCREENING IN YOUNG WOMEN: A RANDOMIZED CONTROLLED TRIAL Chacko MR, Wiemann CM, Kozinetz.
Module 1 General introduction to substitution treatment.
Introduction Results and Conclusions Categorical group comparisons revealed no differences on demographic or social variables. At admission to treatment,
Introduction Results and Conclusions On demographic variables, analyses revealed that ATR clients were more likely to be Hispanic and employed, whereas.
Methamphetamine: User Characteristics and Treatment Response Alice Huber, Ph.D. Steven Shoptaw, Ph.D. Richard A. Rawson, Ph.D. Paul Brethen, M.A. Walter.
Cognitive Behavioral Therapy Enduring Effects and Mechanisms Bruce J. Rounsaville Yale University.
Slide 1 of 19 National Treatment Retention Findings from DATOS Charts Prepared & Released for Public Use by Dwayne Simpson (TCU), Robert Hubbard (NDRI-NC),
The University of Georgia Training and exposure to evidence-based practices: Changing attitudes among the addiction treatment workforce J. Aaron Johnson,
Table 1. Prediction model for maximum daily dose of buprenorphine-naloxone in a 12-week treatment condition Baseline Predictors Maximum Daily Dose Standardized.
Introduction Results and Conclusions Analyses of demographic and social variables revealed that women were more likely to have children, be living in a.
Relational Discord at Conclusion of Treatment Predicts Future Substance Use for Partnered Patients Wayne H. Denton, MD, PhD; Paul A. Nakonezny, PhD; Bryon.
Introduction Results and Conclusions On counselor background variables, no differences were found between the MH and SA COSPD specialists on race/ethnicity,
Substance Use among Older Adults (Age 50+): Current Prevalence and Future Expectations Presented by Joe Gfroerer U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES.
School Improvement Network Impact Assessment: Higher Engagement Schools versus Lower Engagement Schools Steven H. Shaha, PhD, DBA Professor, Center for.
METHADONE VS. NON-METHADONE PATIENTS IN A THERAPEUTIC COMMUNITY: TEST OF EQUIVALENCY James L. Sorensen 1,2, S. Andrews 1,2, K. L. Delucchi 1,3, B. Greenberg.
UCLA Integrated Substance Abuse Programs Richard Rawson, Ph.D. Rachel Gonzales, Ph.D. Funded by: California Alcohol and Drug Programs CalOMS Training for.
Methamphetamine Use Among Offenders Association for Criminal Justice Research (CA) March 17, 2005 Jerry Cartier / David Farabee / Michael Prendergast University.
Ten Years of Pharmacotherapy Trials in the CTN: An Overview.
Predictors of study retention in addiction treatment trials KORTE JE 1, MAGRUDER KM 1,2, KILLEEN TK 1, SONNE SC 1, SAMPSON RR 1 and BRADY KT 1,2 1. Medical.
Factors associated with concurrent Heroin use among patients on Methadone maintenance treatment in Vietnam from 2008 to 2013 Hoang Nam Thai MD, MPH – CDC/DGHT.
Introduction Results and Conclusions Analyses of demographic and social variables indicated that Hispanics were more likely to be male, married, and living.
Buprenorphine {Suboxone®, Subutex®}
Medication Adherence and Substance Abuse Predict 18-Month Recidivism among Mental Health Jail Diversion Program Clients Elizabeth N. Burris 1, Evan M.
Readiness To Change HIV/HCV Risk Behavior Among Young African American IDUs. Edward V Morse, PhD, Tulane University Health Sciences Center, Department.
Trends in Access to Substance Abuse Treatment for Women and Men: Jeanne C. Marsh, PhD, Hee-Choon Shin, PhD, Dingcai Cao, PhD University of Chicago.
Methadone maintenance in Michigan: Five years of data using a contingency management approach Gary Rhodes, M.A., L.L.P. Golfo Tzilos, M.A. Mark Greenwald,
PURPOSE BACKGROUND RESULTS STUDY DESIGN & METHODS HIV Risk Behaviors Among Male Prisoners Participating in a Randomized Clinical Trial of Methadone Maintenance.
Predictors of study retention in drug abuse treatment trials
Ch. 17 Preventing Drug Abuse Section 4 Choosing to be Drug Free
Personality, stress, and social support in cocaine relapse prediction
David Sottile, Anthony DeFulio, and Kenneth Silverman INTRODUCTION
Kristen Williams, Jonathan J.K. Stoltman, and Mark K. Greenwald
Sherry Deren, Sung-Yeon Kang, Milton Mino & Honoria Guarino
SCOPE Training March
The relationship between incarceration and opioid addiction treatment
Florida International University
Medically assisted treatment
Presentation transcript:

C:\laam\lamAPA.ppt 8/04/98 Heroin Addiction Treatment: A Comparison of Methadone and LAAM M. Douglas Anglin, Ph.D. Douglas Longshore, Ph.D. Jeffrey J. Annon, M.A. Richard A. Rawson, Ph.D. UCLA Drug Abuse Research Center American Methadone Treatment Association New York, September , 1998 Supported by NIDA Grant R01-DA10422

of Window of Vulnerability Concept l Within the effective period after each opiate agonist dose, there is less likelihood of injecting heroin. â In the case of methadone, this constitutes the first 12 hours, with increasing likelihood of injection in the subsequent 12 hours. â In the case of LAAM, which has a 48 to 72-hour half-life, this period increases to 36 to 60 hours with the likelihood of injection increasing in the final 12 hours before the next dose. l The “window of vulnerability” is the period of time during which blood levels of the maintenance drug are lowest and the craving for heroin likely to be highest. C:\laam\lamAPA.ppt 8/04/98

Hypotheses l Because of the longer half-life of LAAM, the “window of vulnerability” is smaller for LAAM subjects than for those on methadone. l Thus for clients on LAAM, there will be less drug use, greater retention in treatment, and less high-risk behavior associated with both drug use and withdrawal. C:\laam\lamAPA.ppt 8/04/98

Method l The project is a two-group, repeated-measures experimental design. l Heroin addicts seeking treatment in LA County are randomly assigned in a two to one ratio to either LAAM or methadone under maintenance protocols for 12 months of subsidized care. l Both groups receive all treatment services provided by the dosing clinic. l Subjects are assessed with face-to-face interviews three times during treatment (Intake, 6, and 12 months) and after treatment (18 month post admission follow-up). l Short weekly and monthly interviews are also done, as well as data abstraction of urine analysis, dosing records, and other information in clinic files. C:\laam\lamAPA.ppt 8/04/98

Introduction l The purposes of this study are: â to test the effectiveness of LAAM treatment, compared with the standard methadone maintenance (MM) treatment, in reducing HIV risk behaviors; â to determine the differences in treatment retention and clinic attendance between LAAM and MM treatment and to assess which patient characteristics contribute to optimal performance; â to compare the effectiveness of LAAM and MM treatment in relation to patient characteristics in reducing HIV risk behaviors associated with heroin addiction. C:\laam\lamAPA.ppt 8/04/98

Preliminary Analysis l Descriptive statistics completed on the first 186 clients with Intake interviews. l Retention analysis completed on the first 102 clients who entered and would have completed the planned one year of treatment as of July 31, l Monthly urine tests analyzed for these clients. C:\laam\lamAPA.ppt 8/04/98

Demographics of Clinic Patients (N=186)

Drug Use at Intake (N=186)

HIV Risk Behaviors at Intake (N=186)

Completed Treatment (N=102) % Completed 1 Year p=.074

Retention of Those Reaching 1 Year Anniversary (N=102) Retention in Days p=.05

Reasons for Leaving Treatment (N=102)

Opiate Positives by Quarter Positive UA / number of tests *p<.05 **

Cocaine Positives by Quarter Positive UA / number of tests p=NS

Summary of Findings l LAAM is retaining clients in treatment longer than methadone maintenance clients, and there is a trend toward a higher rate of program completion l There are some differences between MM and LAAM clients in their reasons for leaving treatment. l LAAM clients retained in treatment are using less opiates than MM clients. l LAAM clients may be using more cocaine than MM clients during treatment. C:\laam\lamAPA.ppt 8/04/98

Discussion l The “window of vulnerability” concept, while simple, is a starting point for thinking about how addicts in opiate replacement therapy behave and how and when they are more vulnerable to using drugs and engaging in high risk HIV behaviors. l LAAM Clients stay in treatment longer but the reason may be as a result of easier clinic attendance and not the “window of vulnerability” concept. l However, the lower rate of heroin positive urines suggests some support for the “Window of Vulnerability” idea. l The higher use of cocaine by LAAM patients may be explained by the “chasing the high” phenomenon in which addicts no longer get high from heroin and thus turn to other drugs. C:\laam\lamAPA.ppt 8/04/98

Future Analysis l Survival analysis comparing LAAM and MM patients with other addicts in treatment in the LA area (CADDS). l Comparison of LAAM and MM clients who cease all drug use, clients who cease all opiate use but continue to use cocaine, and clients who never stop using opiates or cocaine. l Sex and ethnic differences in treatment response and retention. l Comparison of the HIV risk behavior of LAAM and MM clients at 6 month follow-up (AMTA). C:\laam\lamAPA.ppt 8/04/98

This is a preliminary report on the first year of a four year study of heroin addicts comparing the differential effects of methadone and levo-alpha-acetyl methadol (LAAM) on retention in treatment and drug use. It is hypothesized that the “window of vulnerability”, the period during which blood levels of the maintenance drug are lowest and craving for heroin highest, is smaller for LAAM subjects than for those on methadone and thus there will be greater retention and less drug use for LAAM maintenance clients. This study is recruiting 320 heroin addicts in the Los Angeles area and randomly assigning them to either a methadone or LAAM maintenance treatment condition. The first 186 clients in the study are 73% male, 15% white, 43% African American and 38% Latino. Of the 102 clients who have reached their one year anniversary date, 43% of the methadone maintenance subjects completed treatment, compared to 62% of the LAAM maintenance subjects. Incarceration continues to be the primary reason for discharge with methadone clients having more incarcerations and “no-shows” than LAAM clients. There was less opiate use during treatment for LAAM clients. Cocaine use may be more prevalent among LAAM clients than those on methadone. Plans for future analysis included survival analysis comparing LAAM and MM patients, contrasting drug use patterns within experimental groups, as well as comparing MM and LAAM HIV risk behavior at six month follow-up. This is a preliminary report on the first year of a four year study of heroin addicts comparing the differential effects of methadone and levo-alpha-acetyl methadol (LAAM) on retention in treatment and drug use. It is hypothesized that the “window of vulnerability”, the period during which blood levels of the maintenance drug are lowest and craving for heroin highest, is smaller for LAAM subjects than for those on methadone and thus there will be greater retention and less drug use for LAAM maintenance clients. This study is recruiting 320 heroin addicts in the Los Angeles area and randomly assigning them to either a methadone or LAAM maintenance treatment condition. The first 186 clients in the study are 73% male, 15% white, 43% African American and 38% Latino. Of the 102 clients who have reached their one year anniversary date, 43% of the methadone maintenance subjects completed treatment, compared to 62% of the LAAM maintenance subjects. Incarceration continues to be the primary reason for discharge with methadone clients having more incarcerations and “no-shows” than LAAM clients. There was less opiate use during treatment for LAAM clients. Cocaine use may be more prevalent among LAAM clients than those on methadone. Plans for future analysis included survival analysis comparing LAAM and MM patients, contrasting drug use patterns within experimental groups, as well as comparing MM and LAAM HIV risk behavior at six month follow-up. Abstract